Clearside Biomedical Net Worth
Clearside Biomedical Net Worth Breakdown | CLSD |
Clearside Biomedical Net Worth Analysis
Clearside Biomedical's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Clearside Biomedical's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Clearside Biomedical's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Clearside Biomedical's net worth analysis. One common approach is to calculate Clearside Biomedical's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Clearside Biomedical's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Clearside Biomedical's net worth. This approach calculates the present value of Clearside Biomedical's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Clearside Biomedical's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Clearside Biomedical's net worth. This involves comparing Clearside Biomedical's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Clearside Biomedical's net worth relative to its peers.
Enterprise Value |
|
To determine if Clearside Biomedical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Clearside Biomedical's net worth research are outlined below:
| Clearside Biomedical generated a negative expected return over the last 90 days | |
| Clearside Biomedical has some characteristics of a very speculative penny stock | |
| Clearside Biomedical has high historical volatility and very poor performance | |
| Clearside Biomedical has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 8.23 M. Net Loss for the year was (32.48 M) with profit before overhead, payroll, taxes, and interest of 7.7 M. | |
| Clearside Biomedical currently holds about 29.03 M in cash with (18.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.48. | |
| Latest headline from thelincolnianonline.com: Insider Buying Clearside Biomedical, Inc. Director Acquires 15,000 Shares of Stock |
Clearside Biomedical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Clearside Biomedical. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Clearside Biomedical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Clearside Biomedical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Clearside Biomedical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Clearside Biomedical backward and forwards among themselves. Clearside Biomedical's institutional investor refers to the entity that pools money to purchase Clearside Biomedical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Assenagon Asset Management Sa | 2024-12-31 | 131.9 K | Pnc Financial Services Group Inc | 2024-12-31 | 108.2 K | Captrust Financial Advisors | 2024-12-31 | 101.2 K | Brown Wealth Management, Llc | 2024-12-31 | 100 K | Northeast Financial Consultants, Inc | 2024-12-31 | 93 K | Citadel Advisors Llc | 2024-09-30 | 71.6 K | Susquehanna International Group, Llp | 2024-12-31 | 59 K | Newman Dignan & Sheerar Inc | 2024-12-31 | 30.1 K | Synovus Financial Corp | 2024-12-31 | 30 K | Vanguard Group Inc | 2024-12-31 | 2.8 M | Carmignac Gestion | 2024-12-31 | 1.9 M |
Follow Clearside Biomedical's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 65.2 M.Market Cap |
|
Project Clearside Biomedical's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.86) | (0.90) | |
| Return On Capital Employed | (0.82) | (0.86) | |
| Return On Assets | (0.86) | (0.90) | |
| Return On Equity | 1.84 | 1.93 |
When accessing Clearside Biomedical's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Clearside Biomedical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Clearside Biomedical's profitability and make more informed investment decisions.
Please note, the presentation of Clearside Biomedical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Clearside Biomedical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Clearside Biomedical's management manipulating its earnings.
Evaluate Clearside Biomedical's management efficiency
Clearside Biomedical has return on total asset (ROA) of (0.4846) % which means that it has lost $0.4846 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (13.1002) %, meaning that it created substantial loss on money invested by shareholders. Clearside Biomedical's management efficiency ratios could be used to measure how well Clearside Biomedical manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.93, whereas Return On Tangible Assets are forecasted to decline to (0.90). At present, Clearside Biomedical's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 15.8 M, whereas Non Currrent Assets Other are forecasted to decline to about 25.6 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.23) | (0.22) | |
| Tangible Book Value Per Share | (0.23) | (0.22) | |
| Enterprise Value Over EBITDA | (4.31) | (4.52) | |
| Price Book Value Ratio | (5.23) | (4.97) | |
| Enterprise Value Multiple | (4.31) | (4.52) | |
| Price Fair Value | (5.23) | (4.97) | |
| Enterprise Value | 77.8 M | 61.2 M |
Leadership at Clearside Biomedical emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue 5.5039 | Revenue | Quarterly Revenue Growth 0.208 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Clearside Biomedical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Clearside Biomedical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Clearside Biomedical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Clearside Biomedical time-series forecasting models is one of many Clearside Biomedical's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Clearside Biomedical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Clearside Biomedical Earnings per Share Projection vs Actual
Clearside Biomedical Corporate Management
| MD MBA | Chief AdvisorRetina | Profile | |
| Jenny Kobin | Head Relations | Profile | |
| FRCOphth FRCS | Chief Officer | Profile | |
| Leslie Zacks | Chief Compliance Officer, General Counsel | Profile | |
| Charles Deignan | Chief Officer | Profile | |
| Susan Coultas | Chief Officer | Profile | |
| Leslie JD | Secretary | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearside Biomedical. If investors know Clearside will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearside Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Revenue Per Share | Quarterly Revenue Growth 0.208 | Return On Assets | Return On Equity |
The market value of Clearside Biomedical is measured differently than its book value, which is the value of Clearside that is recorded on the company's balance sheet. Investors also form their own opinion of Clearside Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Clearside Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearside Biomedical's market value can be influenced by many factors that don't directly affect Clearside Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearside Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearside Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearside Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.